查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Nicorandil的中國市場(2022年～2031年)
市場調查報告書
商品編碼
1105812

Nicorandil的中國市場(2022年～2031年)

Research Report on China's Nicorandil Market, 2022-2031
出版日期: | 出版商: China Research and Intelligence | 英文 50 Pages | 商品交期: 最快1-2個工作天內

價格

中國的Nicorandil的銷售額，2017年～2021年之間以年複合成長率72.4％增加，2021年達到6億1,800萬人民幣(9,270萬美元)。中國所販售Nicorandil有錠劑和注射劑，後者銷售額佔很大的佔有率。

本報告提供中國的Nicorandil市場相關調查分析，市場COVID-19影響，市場規模，主要製造商分析，市場預測等相關資訊。

第1章 Nicorandil的相關概念

  • Nicorandil的適應症
  • 中國的Nicorandil市場開發
  • 中國的Nicorandil的政府核准
  • COVID-19對中國的Nicorandil市場的影響

第2章 中國的Nicorandil的銷售(2017年～2021年)

  • 銷售額
    • 中國整體銷售額
    • 中國的各地區的銷售額
  • 銷售量
    • 中國整體銷售量
    • 中國的各地區的銷售量
  • 中國的Nicorandil的銷售:各投藥形態(2017年～2021年)
    • 注射
    • 錠劑

第3章 中國的主要Nicorandilmeka的分析(2017年～2021年)

  • 市場佔有率的分析
    • 製造商市場佔有率:各銷售額
    • 製造商市場佔有率:各銷售量
  • Beijing Sihuan Kebao Pharmaceutical Co., LTd.
    • 企業簡介
    • 中國的Nicorandil的銷售
  • Chugai Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國的Nicorandil的銷售
  • Xi'an Hanfeng Pharmaceutical Co.，Ltd.
    • 企業簡介
    • 中國的Nicorandil的銷售
  • Henan Topfond Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國的Nicorandil的銷售
  • Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國的Nicorandil的銷售

第4章 中國的各種企業的Nicorandil的銷售價格(2021年～2022年)

  • Beijing Sihuan Kebao Pharmaceutical Co., Ltd (RuiKeXi (R))
  • Chugai Pharmaceutical Co., Ltd. (SIGMART (R))
  • Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin (R))
  • Henan Topfond Pharmaceutical Co., Ltd. (TianFang (R))
  • Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang (R))

第5章 中國的Nicorandil市場預測(2022年～2031年)

  • 市場開發的影響因素
    • COVID-19對市場的影響
    • 推動市場要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
Product Code: 2207582

In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is estimated that the number of patients with coronary heart disease in China exceeded 11 million, and that number keeps rising due to environmental pollution and poor lifestyle habits.

Clinically, WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease), and sudden death.

Angina is a clinical syndrome caused by acute, temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with the prevalence increasing from 5%-7% in women aged 45-64 years to 10%-12% in women aged 65-84 years, and from 4%-7% in men aged 45-64 years to 12%-14% in men aged 65-84 years.

The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.

Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. in 2017, Nicorandil became reimbursable under the Chinese medical insurance.

CRI's survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2021, reaching CNY618 million (USD92.7 million), with a CAGR of 72.4% from 2017 to 2021. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

CRI expects that from 2022 to 2031, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics covered:

  • The Impact of COVID-19 on China's Nicorandil Market
  • Development Environment of Nicorandil in China
  • Sales Volume and value of Nicorandil in China
  • Sales Volume and Value of Nicorandil in China by Region
  • Major Nicorandil Manufacturers in China and Their Market Share
  • Sales Price of Nicorandil in China
  • Prospects of China's Nicorandil Market, 2022-2031

Table of Contents

1 Relevant Concepts of Nicorandil

  • 1.1 Indications of Nicorandil
  • 1.2 Development of China's Nicorandil Market
  • 1.3 Governmental Approval of Nicorandil in China
  • 1.4 The Impact of COVID-19 on China's Nicorandil Market

2 Sales of Nicorandil in China, 2017-2021

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Nicorandil in China by Dosage Form, 2017-2021
    • 2.3.1 Injection
    • 2.3.2 Tablets

3 Analysis of Major Nicorandil Manufacturers in China, 2017-2021

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Nicorandil in China
  • 3.3 Chugai Pharmaceutical Co., Ltd.
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Nicorandil in China
  • 3.4 Xi'an Hanfeng Pharmaceutical Co., Ltd.
    • 3.4.1 Company Profile
    • 3.4.2 Sales of Nicorandil in China
  • 3.5 Henan Topfond Pharmaceutical Co., Ltd.
    • 3.5.1 Company Profile
    • 3.5.2 Sales of Nicorandil in China
  • 3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 3.6.1 Company Profile
    • 3.6.2 Sales of Nicorandil in China

4 Sales Price of Nicorandil of Different Companies in China, 2021-2022

  • 4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®)
  • 4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART®)
  • 4.3 Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®)
  • 4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang®)
  • 4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®)

5 Prospects of China's Nicorandil Market, 2022-2031

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information of Nicorandil in China
  • Chart Sales Value and Volume of Nicorandil in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China by Region, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China by Region, 2017-2021
  • Chart Sales Volume of Nicorandil Injection in China, 2017-2021
  • Chart Sales Volume of Nicorandil Tablets in China, 2017-2021
  • Chart Market Share of Nicorandil Injection Manufacturers in China by Sales Value, 2017-2021
  • Chart Market Share of Nicorandil Tablets Manufacturers in China by Sales Value, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Xi'an Hanfeng Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Henan Topfond Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Price of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Nicorandil in China, 2022-2031
  • Chart Forecast on Sales Volume of Nicorandil in China, 2022-2031